Revolution Medicines presented updated first-line pancreatic ductal adenocarcinoma (PDAC) data alongside earlier late-stage results, reinforcing its push to build a RAS-targeting franchise in one of oncology’s hardest segments. At AACR, the company reported additional Phase I/II findings in previously untreated metastatic PDAC patients, including monotherapy and combination readouts, extending the narrative momentum from its prior Phase 3 success. ClearNote Health, meanwhile, advanced the early-detection track for pancreatic cancer with new performance data on its Avantect Pancreatic Cancer assay. In a validation cohort of 1,445 high-risk patients (including 259 with cancer), the updated test reached 82.6% overall sensitivity and 97.5% specificity, with stage I sensitivity reported in the 60%–70% range depending on cohort. Together, the two updates highlight a double-front push across the PDAC lifecycle: efforts to improve outcomes in advanced disease while simultaneously raising the bar for earlier, actionable detection using blood-based biomarkers.